

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Hu CD19 BUV737 SJ25C1 100Tst

RRID:AB_2870087

Type: Antibody

Proper Citation

BD Biosciences Cat# 612756, RRID:AB_2870087

Antibody Information

URL: http://antibodyregistry.org/AB_2870087

Proper Citation: BD Biosciences Cat# 612756, RRID:AB_2870087

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD19 BUV737 SJ25C1 100Tst

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: SJ25C1 (aka SJ25-C1)

Antibody ID: AB_2870087

Vendor: BD Biosciences

Catalog Number: 612756

Record Creation Time: 20250820T030339+0000

Record Last Update: 20250820T151429+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD19 BUV737 SJ25C1 100Tst.

No alerts have been found for Hu CD19 BUV737 SJ25C1 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lebrec H, et al. (2025) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. iScience, 28(5), 112447.

Van der Meer JMR, et al. (2024) Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. Cytotherapy, 26(2), 136.

Cummings SE, et al. (2024) SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model. iScience, 27(1), 108708.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (New York, N.Y.), 4(2), 113.

Mantus G, et al. (2022) Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell reports. Medicine, 3(4), 100603.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer cell, 39(2), 257.